Bevacizumab and PEG-Interferon Alfa-2b in Treating Patients With Metastatic or Unresectable Carcinoid Tumors

Clinical trial NCT00055809 · COMPLETED

Trial details

NCT number: NCT00055809
Sponsor: National Cancer Institute (NCI)
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Metastatic Gastrointestinal Carcinoid Tumor Recurrent Gastrointestinal Carcinoid Tumor Regional Gastrointestinal Carcinoid Tumor

Start date: 2003-01-01
Primary completion: 2007-06-01
Enrollment: 44

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.